New drug cocktail takes on rare, aggressive breast cancer
NCT ID NCT03202316
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 35 times
Summary
This phase II trial tests whether combining an immunotherapy (atezolizumab), a targeted therapy (cobimetinib), and a chemotherapy (eribulin) can shrink tumors in people with inflammatory breast cancer that has returned or spread. About 37 participants will receive either the triple combo or a double combo (atezolizumab plus eribulin). The main goal is to see how many patients respond, while also monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT BREAST INFLAMMATORY CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
atezolizumab, cobimetinib, and eribulin
What this could lead to
If successful, this could point toward a new combination treatment for inflammatory breast cancer that has spread, potentially improving response rates.
What could go wrong
This is a small, early-phase trial (37 people) with no control group, so results may not apply broadly. Side effects from the drug combination could be significant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.